絞り込み

16417

広告

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.

著者 Ninomiya T , Nogami N , Kozuki T , Harada D , Kubo T , Ohashi K , Kuyama S , Kudo K , Bessho A , Fukamatsu N , Fujimoto N , Aoe K , Shibayama T , Sugimoto K , Takigawa N , Hotta K , Kiura K
Lung Cancer.2018 Jan ; 115():103-108.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (23view , 0users)

Full Text Sources

Miscellaneous

In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase inhibitor (TKI), confers a significant survival benefit over platinum-based chemotherapy. The first-generation EGFR-TKIs gefitinib and erlotinib in combination with bevacizumab have improved progression-free survival. We hypothesized that the combination of afatinib with bevacizumab would further improve efficacy, and conducted a phase I trial to test this hypothesis.
PMID: 29290249 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード